| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/15/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/15/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/21/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"CERTIFICATE OF DESIGNATIONS OF CONVERTIBLE PREFERRED STOCK OF",
"Form of Warrant Neither the issuance and sale of the securities represented by this certificate nor the securities into which these securities are exercisable have been registered under the securities act of 1933, as amended, or applicable state securities laws. The securities may not be offered for sale, sold, transferred or assigned in the absence of an effective registration statement for the securities under the securities act of 1933, as amended, or an opinion of counsel to the holder , in a form reasonably acceptable to the company, that registration is not required under said act or unless sold or eligible to be sold pursuant to rule 144 or rule 144a under said act. Notwithstanding the foregoing, the securities may be pledged in connection with a bona fide margin account or other lo...",
"RECITALS",
"Registration Rights Agreement",
"Petros Pharmaceuticals Announces Capital Raise of $15 million" |
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
4
| Bradley Greg (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 6,050 restricted stock units
@ $0 |
|
| 04/28/2023 |
4
| Bernstein Bruce (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 6,050 restricted stock units
@ $0 |
|
| 04/28/2023 |
4
| WALKER WAYNE REMELL (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 6,050 restricted stock units
@ $0 |
|
| 04/28/2023 |
4
| Silverman Joshua (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 6,722 restricted stock units
@ $0 |
|
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 7.6% stake in Petros Pharmaceuticals, Inc. |
| 01/25/2023 |
4
| WALKER WAYNE REMELL (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 2,264 restricted stock units
@ $0 |
|
| 01/25/2023 |
4
| Silverman Joshua (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 2,515 restricted stock units
@ $0 |
|
| 01/25/2023 |
4
| Bradley Greg (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 2,264 restricted stock units
@ $0 |
|
| 01/25/2023 |
4
| Bernstein Bruce (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.|
Txns:
| Exercised 2,264 restricted stock units
@ $0 |
|
| 11/30/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q/A
| Quarterly Report for the period ended September 30, 2022 [amend] |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/14/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/12/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/12/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/30/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/24/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|